Today: 7 July 2026
Browse Category

NASDAQ:ATAI 18 October 2025 - 16 June 2026

AtaiBeckley climbs after kicking off Phase 3 for BPL-003 in depression

AtaiBeckley climbs after kicking off Phase 3 for BPL-003 in depression

AtaiBeckley Inc. jumped 7.8% to $4.14 on Tuesday. Chief Executive Srinivas Rao said the company’s lead depression drug, BPL-003, advanced into Phase 3 trials. ATAI shares on Nasdaq moved between $3.83 and $4.34. Volume was close to 10 million shares. This is important as the company has moved from the planning stage to executing on its core asset. Phase 3 is the late-stage human trial, often the final hurdle for approval if the results hold up.
16 June 2026
·
Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Atai shares exploded higher on Oct. 17, 2025. Investors bid the stock up ~17.7%, closing at roughly $6.45 ts2.tech. In after-hours trading it briefly touched ~$6.86 ts2.tech. This rally follows a week of good news: BPL-003’s FDA breakthrough, plus well-received capital raise plans. Volume on Oct. 17 was very high, reflecting heavy trading. Over 2025 the stock has skyrocketed ~348% ts2.tech, making ATAI one of the year’s top biotech performers. Its market cap now hovers around $1.2 billion ts2.tech. Analysts have taken notice. Needham Research just initiated ATAI as a Buy with a $12 target benzinga.com, noting ample cash and strong data. H.C. Wainwright maintains a Buy with a $15 target stockanalysis.com. In fact, 5 covering analysts rate ATAI a Strong Buy on average stockanalysis.com, implying roughly 100% upside. This aligns with a consensus price target of about $13–$14 stockanalysis.com, far above the current price. Some strategists caution that issuing ~15–20% more shares could temporarily weigh on the stock, but most agree the financing was smartly timed to fund R&D ts2.tech. Notably, ARK Innovation bought ~250K shares on the news stockstotrade.com, signaling strong institutional interest.
18 October 2025
·
ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion

ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion

ATAI’s stock price surged in the last few days amid a flurry of good news. Shares jumped 17.7% on Friday alone, finishing at $6.45marketbeat.com, after trading around the mid-$5 range earlier in the week. In fact, as of early Friday, ATAI was already up about 8% for the week on anticipation of the announcementsnasdaq.com. The strong finish came as investors digested multiple catalysts: a coveted FDA designation for a key drug, a fresh capital raise, and bullish commentary from analysts. Notably, after-hours trading on Friday saw ATAI climb further to $6.86, indicating continued buying momentum heading into the weekendmarketbeat.com. This rally caps an extraordinary year for ATAI. The stock has now skyrocketed roughly 348% in 2025investing.com, making it one of the standout performers in the biotech space. The company’s focus on psychedelic-based mental health treatments – once a niche area – has attracted growing investor interest as clinical results improve and regulatory attitudes warm. ATAI’s market capitalization now stands around $1.2 billioninvesting.com, up from mere few hundred million at the start of the year. Such rapid appreciation underscores the high-risk, high-reward nature of clinical-stage biotech stocks. Traders have been willing to pile in on positive headlines, though volatility remains high.
18 October 2025
·

Stock Market Today

  • SK Hynix Drops 6.7% Ahead of U.S. Nasdaq Debut as Investors Worry Over IPO and Industry Risks
    July 7, 2026, 12:29 AM EDT. SK Hynix slid 6.7% in Asian trading July 7, days before its U.S. listing on July 10. The stock, which had jumped after the June 30 IPO announcement, has dropped from 2.749 million Korean won to 2.05 million-a 25% plunge-on concerns about macroeconomic headwinds, possible IPO dilution, and short-lived sentiment. Investors grew cautious as tech giants put money into AI data centers with few clear payoffs now, while big planned spending from Samsung and SK Hynix and talk of oversupply weighed. SK Hynix cut the reference IPO price, adding to the pressure. The company is set for inclusion in the Philadelphia Semiconductor Index, which could draw passive fund buyers and help the stock, but some see more downside if those inflows don't come through.
Go toTop